DRL says cap on trade margins a positive, posts 36% dip in Q2 PAT
Reported by Economic Times Markets, not nibnow. We are not the publisher of this story, only the source is.
Dr. Reddy's Labs reported a 36% drop in quarterly profit, and its support for new trade‑margin caps could influence drug pricing and access to medicines.
In the second quarter of FY2027, Dr. Reddy's Labs experienced a downturn in both revenue and profit. However, the company supports new trade margin regulations that aim to improve access to vital medicines. With a commitment to boosting its core business performance, management is also dedicated to exploring growth avenues.
Dr. Reddy's Labs is a major Indian pharmaceutical manufacturer; trade‑margin regulations set limits on the profit distributors can add, aiming to keep essential medicines affordable.
- •How the trade‑margin cap is implemented and its impact on drug prices
- •Updates on Dr. Reddy's strategies to revive core business performance
- •The company's next quarterly earnings report